Dragon Claws U.S. federal prosecutors charged 30 lawyers and financial professionals in a decade-long insider trading scheme that allegedly generated tens of millions of dollars in illegal profits, the Financial Times reported. Two indictments unsealed in Boston accused the group of using confidential information tied to nearly 30 corporate deals. While the filings did not name specific firms, the...
Dragon Claws U.S. federal prosecutors charged 30 lawyers and financial professionals in a decade-long insider trading scheme that allegedly generated tens of millions of dollars in illegal profits, the Financial Times reported. Two indictments unsealed in Boston accused the group of using confidential information tied to nearly 30 corporate deals. While the filings did not name specific firms, the transactions cited pointed to involvement from top Wall Street legal advisers, including Latham & Watkins, Goodwin Procter, and Wachtell Lipton. Prosecutors alleged that Nicolo Nourafchan, a Yale Law School graduate who worked at several major firms, accessed sensitive deal information through internal systems and colleagues and passed it to a broader network. He also allegedly recruited his college associate Robert Yadgarov, who helped expand the circle of tipsters. The scheme spanned high-profile deals, including Cigna’s ( CI ) $54B acquisition of Express Scripts and Johnson & Johnson’s ( JNJ ) $30B purchase of Actelion. Other transactions cited included Occidental Petroleum’s ( OXY ) $55B takeover of Anadarko and the $11B Burger King-Tim Hortons merger. The case came as regulators intensified scrutiny of suspicious trading activity across markets. The Department of Justice, alongside the Commodity Futures Trading Commission, was investigating a series of suspiciously timed oil market trades that occurred just before major announcements regarding the Iran conflict, according to a media report published Thursday. “Everyone charged today is accused of scoring significant profits from expected market moves and making out like bandits,” Ted Docks, special agent in charge of the FBI’s Boston division, said. The case highlighted growing concerns around the misuse of non-public information in both corporate dealmaking and broader geopolitical markets, particularly as volatility tied to war, energy, and diplomacy created opportunities for outsized gains. More on markets USD Rema...
Entain wants no operators unlicensed in UK as sponsors Two clubs did not advertise such companies this season The Independent Football Regulator (IFR) has been urged to stop Premier League clubs from accepting sponsorship from gambling companies unlicensed in the UK in the latest public consultation over its licensing regime. Entain, the global sports betting company that owns Ladbrokes and Coral,...
Entain wants no operators unlicensed in UK as sponsors Two clubs did not advertise such companies this season The Independent Football Regulator (IFR) has been urged to stop Premier League clubs from accepting sponsorship from gambling companies unlicensed in the UK in the latest public consultation over its licensing regime. Entain, the global sports betting company that owns Ladbrokes and Coral, has submitted a response to the IFR asking for a clarification of its guidance that would prevent clubs from doing commercial deals with operators unlicensed in the UK. Continue reading...
According to the job research firm Challenger, Gray & Christmas, job cuts rose 38% in April compared to March. Much of this was blamed on AI-driven layoffs. The April number reached 83,387. The number was the third-highest figure since 2009, during the Great Recession. Andy Challenger said, “Technology companies continue to announce large-scale cuts and ... April Job Cuts Surge 38% On AI Downsizin...
According to the job research firm Challenger, Gray & Christmas, job cuts rose 38% in April compared to March. Much of this was blamed on AI-driven layoffs. The April number reached 83,387. The number was the third-highest figure since 2009, during the Great Recession. Andy Challenger said, “Technology companies continue to announce large-scale cuts and ... April Job Cuts Surge 38% On AI Downsizing
Hedge funds are staging a dramatic rebound after suffering hefty losses during March's Middle East-fueled market mayhem, with equity-focused strategies landing their biggest monthly gain for investors in a quarter-century last month. Overall, the industry advanced about 3% on average in April, according to new data published by global industry tracker Hedge Fund Research. "We saw in April a histor...
Hedge funds are staging a dramatic rebound after suffering hefty losses during March's Middle East-fueled market mayhem, with equity-focused strategies landing their biggest monthly gain for investors in a quarter-century last month. Overall, the industry advanced about 3% on average in April, according to new data published by global industry tracker Hedge Fund Research. "We saw in April a historic performance recovery for hedge funds from a historic decline in the prior month of March," said HFR president Kenneth Heinz. Among the industry's big winners were equity hedge funds — a cornerstone strategy in which managers invest both long and short on listed companies. Short selling involves investors betting against a particular stock or security, with the aim of profiting from a decline in its value. Here, stockpickers notched a standout 5.43% monthly return in April, a sharp rebound from March's 4.33% slide. This was also their strongest monthly showing since February 2000, which Heinz described as "an amazing performance." BlackRock back hedge funds Hedge funds suffered steep losses in March, with their portfolio positions caught out by the Middle East conflict and resulting oil price spike. HFR's all-strategy index lost almost 3% for the month, marking its biggest dip since June 2022. .SPX line 2026-03-01 Stocks have staged a rebound after losses in March. But in its latest performance update, Heinz pinpointed three key drivers underpinning hedge funds' strong run in recent weeks: the market rally sparked by the Middle East ceasefire agreed April 8; a "powerful return" of the AI and technology trade; and growing expectations of a flurry of IPO activity in the coming months. More broadly, the all-strategy HFRX Global Hedge Fund Index — a tradeable benchmark which measures overall industry performance across all investment strategies and approaches — advanced 2.98% in April after suffering a 2.95% loss in March. Heinz said: "In February and March there was a lot of...
Michael Vi/iStock Editorial via Getty Images In the leadup to British semiconductor major Arm Holdings plc's ( NASDAQ : ARM ) FY 2026 earnings release - made on the 6th of May after market close - the stock had risen by an astounding 60%. The earnings release, on the other hand, seems to have more-or-less only mildly exceeded analyst consensus: revenue for its fourth quarter (Q2) was $1.49 billion...
Michael Vi/iStock Editorial via Getty Images In the leadup to British semiconductor major Arm Holdings plc's ( NASDAQ : ARM ) FY 2026 earnings release - made on the 6th of May after market close - the stock had risen by an astounding 60%. The earnings release, on the other hand, seems to have more-or-less only mildly exceeded analyst consensus: revenue for its fourth quarter (Q2) was $1.49 billion versus an expectation of $1.47 billion while adjusted earnings per share (EPS) $0.60 versus an expectation of $0.58. The trends and the messaging are potentially either at odds or represent a massive shift in direction. Trend Drilldown At first blush, trends seem to indicate that the company's massive growth spurt in net income in FY25 isn't going to be repeated. Source: Created by Sandeep G. Rao using data from Arm's Financial Statements However, this isn't quite the case and entirely explainable by the nature of Arm, which is a fabless holder of Intellectual Property (IP) and designs employed in chip design and manufacturing. Once a design is finished and the IP is acquired, it is a comparatively minor cost to deliver it to a chipmaker or foundry. The human factor - and with it, Stock-Based Compensation (SBC) - becomes very relevant, particularly in FY 24, i.e. the year Arm had its Initial Public Offering (IPO). The company spent nearly $1.04 billion in SBC for FY24 as employee equity vested. Furthermore, legal, banking, and administrative fees associated with the IPO also ate into the bottom line (i.e. net income). In FY25, SBC was $820 million. Because SBC is an expense, a decrease in SBC directly increases Net Income. If " Adjusted Profit " were estimated for both these years by adding SBC back to Net Income from continuing operations, the " Adjusted Profit " for FY24 and FY25 would be $1.343 billion and $1.612 billion respectively, i.e. a 20% growth in profit relative to a 24% growth in revenue. Adding back the reported $1.052 billion in SBC to net income from contin...
Lightspeed Commerce ( LSPD ) on Thursday said it appointed Bhawna Singh as chief technology officer as the company pushes ahead with new AI, payments, and wholesale product initiatives. Singh most recently served as CTO at Okta ( OKTA ), where she led technology strategy for the company’s customer identity platform, and earlier held the CTO role at Glassdoor. Lightspeed said the leadership appoint...
Lightspeed Commerce ( LSPD ) on Thursday said it appointed Bhawna Singh as chief technology officer as the company pushes ahead with new AI, payments, and wholesale product initiatives. Singh most recently served as CTO at Okta ( OKTA ), where she led technology strategy for the company’s customer identity platform, and earlier held the CTO role at Glassdoor. Lightspeed said the leadership appointment comes alongside a new wave of product updates aimed at helping retail and hospitality businesses improve operations, manage inventory, and streamline customer experiences across sales channels. More on Lightspeed Commerce Inc. Lightspeed Commerce Inc. (LSPD:CA) Discusses Divestiture of Upserve U.S. Hospitality Product Line and Strategic Refocus Transcript Lightspeed Grows Revenue, But Valuation Compression Worsens As Operating Losses Rise Historical earnings data for Lightspeed Commerce Inc. Financial information for Lightspeed Commerce Inc.
Guardian Pharmacy Services press release ( GRDN ): Q1 Non-GAAP EPS of $0.29 beats by $0.05 . Revenue of $336.6M beats by $6.71M . Net Income of $13.5M. Adjusted EBITDA of $29.8M. The company has raised annual adjusted EBITDA forecast midpoint to $125 million from $122 million; maintained revenue outlook midpoint at $1.41 billion. More on Guardian Pharmacy Services Guardian Pharmacy Services, Inc. ...
Guardian Pharmacy Services press release ( GRDN ): Q1 Non-GAAP EPS of $0.29 beats by $0.05 . Revenue of $336.6M beats by $6.71M . Net Income of $13.5M. Adjusted EBITDA of $29.8M. The company has raised annual adjusted EBITDA forecast midpoint to $125 million from $122 million; maintained revenue outlook midpoint at $1.41 billion. More on Guardian Pharmacy Services Guardian Pharmacy Services, Inc. (GRDN) Q1 2026 Earnings Call Transcript Guardian Pharmacy Services: Waiting For A Better Entry Point Guardian Pharmacy Services, Inc. (GRDN) Q4 2025 Earnings Call Transcript Guardian Pharmacy Services forecasts $123M-$127M adjusted EBITDA amid ira pricing reset Healthcare quant check: RLAY and TNGX lead Seeking Alpha’s top picks ahead of Q1 earnings
PonyWang/iStock Unreleased via Getty Images Back in February, I double upgraded Tesla, Inc. ( TSLA ) from a sell rating to a buy rating, citing a strategic renaissance and a valuation that wasn't as high as it seemed. You can see in the chart below that the stock has experienced some very modest losses since then despite the recent rebound, and so performance hasn't been as strong as I envisioned....
PonyWang/iStock Unreleased via Getty Images Back in February, I double upgraded Tesla, Inc. ( TSLA ) from a sell rating to a buy rating, citing a strategic renaissance and a valuation that wasn't as high as it seemed. You can see in the chart below that the stock has experienced some very modest losses since then despite the recent rebound, and so performance hasn't been as strong as I envisioned. The company reported their latest batch of earnings in late April and also shared some key developments recently, and so today I have decided to provide an update to see if the bull thesis still stands. Seeking Alpha Below, it is shown that Tesla's legacy automotive business is back on steadier footing. With their FSD also performing well, top-line growth is at multiyear highs, and their margins are also expanding. All eyes are on Cybercab and Optimus, and the reported progress didn't disappoint. With the long-term growth story getting increasingly clear, the contraction in the valuation since my previous article has made the risk/reward potentially even more attractive. Therefore, I'm reiterating my buy rating on Tesla stock. Best Growth In Recent Memory Data by YCharts Starting with the top-line results, Tesla saw some encouraging signs in their 2026 Q1. The Musk-led company posted revenues of $22.39 billion, which represents a growth rate of 16% YoY. While this isn't the strongest growth we have ever seen, it is shown above that there has been significant improvement from the previous quarter. In fact, this is the best growth rate that we have seen since mid-2023, and so really there has been a material step-up in their business activity overall. Furthermore, Tesla beat top-line expectations by a nice margin of $178.89 million, and so there was some outperformance. While it seems that their growth has been quite erratic in recent quarters, investors shouldn't forget that EV incentives ended last fall, and so Q3 results were artificially inflated while Q4 results were pr...
PonyWang/iStock Unreleased via Getty Images Back in February, I double upgraded Tesla, Inc. ( TSLA ) from a sell rating to a buy rating, citing a strategic renaissance and a valuation that wasn't as high as it seemed. You can see in the chart below that the stock has experienced some very modest losses since then despite the recent rebound, and so performance hasn't been as strong as I envisioned....
PonyWang/iStock Unreleased via Getty Images Back in February, I double upgraded Tesla, Inc. ( TSLA ) from a sell rating to a buy rating, citing a strategic renaissance and a valuation that wasn't as high as it seemed. You can see in the chart below that the stock has experienced some very modest losses since then despite the recent rebound, and so performance hasn't been as strong as I envisioned. The company reported their latest batch of earnings in late April and also shared some key developments recently, and so today I have decided to provide an update to see if the bull thesis still stands. Seeking Alpha Below, it is shown that Tesla's legacy automotive business is back on steadier footing. With their FSD also performing well, top-line growth is at multiyear highs, and their margins are also expanding. All eyes are on Cybercab and Optimus, and the reported progress didn't disappoint. With the long-term growth story getting increasingly clear, the contraction in the valuation since my previous article has made the risk/reward potentially even more attractive. Therefore, I'm reiterating my buy rating on Tesla stock. Best Growth In Recent Memory Data by YCharts Starting with the top-line results, Tesla saw some encouraging signs in their 2026 Q1. The Musk-led company posted revenues of $22.39 billion, which represents a growth rate of 16% YoY. While this isn't the strongest growth we have ever seen, it is shown above that there has been significant improvement from the previous quarter. In fact, this is the best growth rate that we have seen since mid-2023, and so really there has been a material step-up in their business activity overall. Furthermore, Tesla beat top-line expectations by a nice margin of $178.89 million, and so there was some outperformance. While it seems that their growth has been quite erratic in recent quarters, investors shouldn't forget that EV incentives ended last fall, and so Q3 results were artificially inflated while Q4 results were pr...
Snowflake (NYSE: SNOW) is trying to become the platform where enterprise data and AI workflows come together. The opportunity could be massive if customers use its tools more deeply, but the stock still carries premium expectations. This setup makes Snowflake one of the more compelling and risky AI software stories for investors right now. Stock prices used were the market prices of April 27, 2026...
Snowflake (NYSE: SNOW) is trying to become the platform where enterprise data and AI workflows come together. The opportunity could be massive if customers use its tools more deeply, but the stock still carries premium expectations. This setup makes Snowflake one of the more compelling and risky AI software stories for investors right now. Stock prices used were the market prices of April 27, 2026. The video was published on May 4, 2026. Continue reading
Per Scholas today announced a new collaboration with Microsoft to launch its first-ever Critical Infrastructure cohort, a 15-week, intensive training program designed to prepare learners for high-demand roles supporting the systems that power today's digital economy.
Per Scholas today announced a new collaboration with Microsoft to launch its first-ever Critical Infrastructure cohort, a 15-week, intensive training program designed to prepare learners for high-demand roles supporting the systems that power today's digital economy.
chinaface/E+ via Getty Images Canadian Natural Resources ( CNQ ) down 1.4% pre-market Thursday despite reporting better-than-expected Q1 adjusted earnings of C$1.17/share, topping the C$1.05/share analyst forecast by FactSet, fueled by higher production in its oil sands segment as well as conventional operations; shares are lower as crude oil prices fell on reports that the U.S. and Iran may be n...
chinaface/E+ via Getty Images Canadian Natural Resources ( CNQ ) down 1.4% pre-market Thursday despite reporting better-than-expected Q1 adjusted earnings of C$1.17/share, topping the C$1.05/share analyst forecast by FactSet, fueled by higher production in its oil sands segment as well as conventional operations; shares are lower as crude oil prices fell on reports that the U.S. and Iran may be nearing an agreement to end the Middle East war. Q1 net earnings fell to C1.35B (~US$988M), or C$0.64/share, from C$2.46B, or C$1.17/share, in the year-earlier quarter, weighed by C$1.1B in non-operating losses related to items including the effects of share-based compensation, risk management activities, and fluctuations in foreign exchange rates, while product sales slipped to C$12.4B from C$12.71B in the same period last year. Q1 total production before royalties rose 3.8% Y/Y to 1.64M boe/day, in line with its previously announced full-year output target of 1.615M-1.665M boe/day, as crude oil and natural gas liquids volumes edged up to nearly 1.2M bbl/day while gas production before royalties jumped 8.9% to 2.67B cf/day. Results were helped by record production of 134,396 bbl/day from the Jackfish thermal oil sands project, exceeding its maximum output capacity, record quarterly North American natural gas production of 2.67B cf/day, and higher oil sands production of ~630K bbl/day, with facilities running above full capacity. Canadian Natural ( CNQ ) said its realized crude oil and natural gas liquids prices fell 5% Y/Y but rose 18% Q/Q, while the realized sales price in its oil sands mining and upgrading segment fell 6% Y/Y but increased 18% Q/Q. The company said higher commodity prices have helped it accelerate debt reduction, with net debt falling below C$16B, and accelerated the pace of share buybacks, with C$309M of shares repurchased in April. More on Canadian Natural Resources Canadian Natural Resources: Earnings Set To Reveal Massive Rewards Canadian Natural Res...
Theravance Biopharma press release ( TBPH ): Q1 GAAP EPS of -$0.10 misses by $0.13 . Revenue of $17.7M (+14.9% Y/Y) beats by $0.25M . More on Theravance Biopharma Theravance Biopharma: A Special Situation With A 50-100% Likely Upside Summers Value Fund adds TBPH, exits ADMA among Q1 moves Theravance drops rare disease drug after late-stage trial setback Seeking Alpha’s Quant Rating on Theravance B...
Theravance Biopharma press release ( TBPH ): Q1 GAAP EPS of -$0.10 misses by $0.13 . Revenue of $17.7M (+14.9% Y/Y) beats by $0.25M . More on Theravance Biopharma Theravance Biopharma: A Special Situation With A 50-100% Likely Upside Summers Value Fund adds TBPH, exits ADMA among Q1 moves Theravance drops rare disease drug after late-stage trial setback Seeking Alpha’s Quant Rating on Theravance Biopharma Historical earnings data for Theravance Biopharma